Skip to main content
Premium Trial:

Request an Annual Quote

Mirna Picks up Additional Rights to Marina Delivery Technology

Premium

Marina Biotech and Mirna Therapeutics this week announced that they have amended an existing licensing agreement to give Mirna greater access to Marina's Smarticle liposomal delivery technology for use with microRNA-based therapeutics.

In early 2012, the companies first inked their deal, which gave Mirna the right to use the delivery technology with its lead cancer candidate, the phase I miRNA mimic MRX34.

Under the terms of the amended arrangement, Mirna has made certain payments to Marina in exchange for additional undisclosed rights to the Smarticle technology as it relates to the MRX34 program. Further, Mirna has obtain the exclusive rights to the technology with "several" additional unnamed tumor-suppressor miRNA targets.

Additional details were not disclosed.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.